Detection of activated EGFR by immunohistochemistry in NSCLC patients is limited by the specificity of phospho-EGFR antibodies, since multiple tyrosine residues on EGFR can be phosphorylated [31]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.